Literature DB >> 22307848

Diarrhea predicts a positive response to sorafenib in patients with advanced hepatocellular carcinoma.

Dominik Bettinger, Michael Schultheiss, Eva Knüppel, Robert Thimme, Hubert E Blum, Hans Christian Spangenberg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22307848     DOI： 10.1002/hep.25637

Source DB:  PubMed          Journal:  Hepatology        ISSN： 0270-9139            Impact factor:   17.425


× No keyword cloud information.
  25 in total

Review 1.  Prognostic significance of adverse events in patients with hepatocellular carcinoma treated with sorafenib.

Authors:  Alessandro Granito; Sara Marinelli; Giulia Negrini; Saverio Menetti; Francesca Benevento; Luigi Bolondi
Journal:  Therap Adv Gastroenterol       Date:  2016-03       Impact factor: 4.409

Review 2.  Sorafenib for the treatment of hepatocellular carcinoma.

Authors:  Marcus Alexander Wörns; Peter Robert Galle
Journal:  Hepat Oncol       Date:  2014-03-20

3.  TKIs beyond immunotherapy predict improved survival in advanced HCC.

Authors:  Samantha Armstrong; Tina Roy; Bhavana Singh; Monika Kulasekaran; Fatima Shaukat; Xue Geng; Hongkun Wang; Petra Prins; Reena C Jha; Marion L Hartley; Aiwu Ruth He
Journal:  J Cancer Res Clin Oncol       Date:  2022-06-30       Impact factor: 4.553

4.  Recent Progress in Systemic Therapy for Hepatocellular Cancer (HCC).

Authors:  T Tara Ghaziani; Renumathy Dhanasekaran
Journal:  Curr Treat Options Gastroenterol       Date:  2021-03-31

5.  Impact of Baseline Characteristics on the Overall Survival of HCC Patients Treated with Sorafenib: Ten Years of Experience.

Authors:  Giulia Rovesti; Giulia Orsi; Andrikou Kalliopi; Caterina Vivaldi; Giorgia Marisi; Luca Faloppi; Francesco Giuseppe Foschi; Nicola Silvestris; Irene Pecora; Giuseppe Aprile; Eleonora Molinaro; Laura Riggi; Paola Ulivi; Matteo Canale; Alessandro Cucchetti; Emiliano Tamburini; Giorgio Ercolani; Lorenzo Fornaro; Pietro Andreone; Patrizia Zavattari; Mario Scartozzi; Stefano Cascinu; Andrea Casadei-Gardini
Journal:  Gastrointest Tumors       Date:  2019-09-12

6.  Clinical factors related to long-term administration of sorafenib in patients with hepatocellular carcinoma.

Authors:  Shunsuke Nojiri; Atsunori Kusakabe; Kei Fujiwara; Noboru Shinkai; Kentaro Matsuura; Etsuko Iio; Tomokatsu Miyaki; Tomoyuki Nomura; Satoshi Sobue; Hitoshi Sano; Izumi Hasegawa; Tomoyoshi Ohno; Yoshitsugu Takahashi; Etsuro Orito; Takashi Joh
Journal:  Cancer Manag Res       Date:  2012-12-18       Impact factor: 3.989

7.  Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma.

Authors:  Giovan Giuseppe Di Costanzo; Andrea Casadei Gardini; Giorgia Marisi; Francesco Giuseppe Foschi; Mario Scartozzi; Rocco Granata; Luca Faloppi; Stefano Cascinu; Nicola Silvestris; Oronzo Brunetti; Vincenzo Ostilio Palmieri; Giorgio Ercolani; Raffaella Tortora
Journal:  Target Oncol       Date:  2017-12       Impact factor: 4.864

8.  Hand-foot-skin reaction of grade ≥ 2 within sixty days as the optimal clinical marker best help predict survival in sorafenib therapy for HCC.

Authors:  Enxin Wang; Dongdong Xia; Wei Bai; Zhexuan Wang; Qiuhe Wang; Lei Liu; Wenjun Wang; Jie Yuan; Xiaomei Li; Hui Chen; Yong Lv; Jing Niu; Chuangye He; Wengang Guo; Zhanxin Yin; Bohan Luo; Na Han; Zhengyu Wang; Tianlei Yu; Xulong Yuan; Kai Li; Jun Tie; Chanjuan Li; Hongwei Cai; Jielai Xia; Daiming Fan; Guohong Han
Journal:  Invest New Drugs       Date:  2018-07-18       Impact factor: 3.651

9.  A systematic review and meta-analysis of the risk of diarrhea associated with vandetanib treatment in carcinoma patients.

Authors:  Zijun Huo; Shuang Yu; Shubin Hong; Xiaopei Cao; Lingling Xiu; Zhihong Liao; Yanbing Li; Haipeng Xiao
Journal:  Onco Targets Ther       Date:  2016-06-20       Impact factor: 4.147

10.  Early diarrhoea under sorafenib as a marker to consider the early migration to second-line drugs.

Authors:  Álvaro Díaz-González; Víctor Sapena; Loreto Boix; Ferrán Torres; Marco Sanduzzi-Zamparelli; Leonardo G Da Fonseca; Neus LLarch; Gemma Iserte; Cassia Guedes; Sergio Muñoz-Martínez; Anna Darnell; Ernest Belmonte; Jordi Rimola; Alejandro Forner; Carmen Ayuso; Jordi Bruix; María Reig
Journal:  United European Gastroenterol J       Date:  2021-07-06       Impact factor: 4.623
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.